Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Promotes Global R&D VP Mackay To Head Unit, Opens Biotech Center

Executive Summary

Pfizer, as part of its ongoing efforts to reinvent its R&D model, is aiming to accelerate product development under a new leadership team and establish a significant presence in biotechnology with a new facility devoted to "bioinnovation.
Advertisement

Related Content

Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain
Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model
Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet”
Fill It Up: Pfizer To Consider More Flexible Deals, Alliances To Bolster Pipeline
Pfizer/Sanofi speculation
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget
Pfizer’s Manufacturing Cost-Cutting May Leave Little Capacity For Growth
Pfizer’s Manufacturing Cost-Cutting May Leave Little Capacity For Growth
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet
Advertisement
UsernamePublicRestriction

Register

PS048870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel